The CFO appointment is a routine executive transition following an interim period. While the $5 million in equity grants represents a significant compensation package, the appointment itself is expected to ensure leadership continuity rather than signal a strategic shift. Traders should monitor the company's progress toward product commercialization, as this triggers vesting of a significant portion of DeTore's performance stock units.
Price Chart
Executive Summary
CG Oncology appointed Jim DeTore as Chief Financial Officer, effective April 13, 2026. The appointment follows his interim role since November 2025 and includes a formal employment agreement with a $520,000 annual base salary and $5 million in initial equity awards.
Key Facts
- Jim DeTore was formally appointed Chief Financial Officer effective April 13, 2026
- DeTore had been serving as Interim Principal Financial and Accounting Officer since November 2025
- He receives a $520,000 annual base salary and is eligible for a 45% target annual bonus
- He received an initial stock option grant valued at $4 million and a performance stock unit award valued at $1 million
- The PSU award vests 30% upon first U.S. commercial sale of the company's first approved product and 70% upon achievement of positive operating cash flow for two consecutive quarters post-launch
Financial Impact
Initial equity awards totaling $5 million ($4 million stock options, $1 million in PSUs) and $520,000 annual base salary
Risk Factors
- Potential for executive turnover if performance expectations are not met
- Dilution from the $5 million in new equity grants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152044 |
| Document: ck0001991792-20260413.htm | 0001193125-26-152044 |
| Document: 0001193125-26-152044-index-headers.html | 0001193125-26-152044 |
| Document: 0001193125-26-152044-index.html | 0001193125-26-152044 |
| Document: 0001193125-26-152044.txt | 0001193125-26-152044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Aug 6, 2026 8w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $67.38 (+9.98%) |
Jul 27, 2026 9w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $67.38 (−7.22%) |
Jul 17, 2026 11w ago | Insider Cluster | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $67.38 (−6.22%) |
Jul 16, 2026 11w ago | Court Ruling | $69.50 $74.71 | ▲ +7.50% | ▲ +3.88% | $67.38 (−3.05%) |
Jun 24, 2026 14w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $67.38 (−7.50%) |
Jun 22, 2026 14w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $67.38 (+2.51%) |
Jun 12, 2026 16w ago | Institutional Cluster | $59.56 $75.24 | ▲ +26.33% | ▲ +24.55% | $67.38 (+13.13%) |
May 26, 2026 18w ago | 8-K | $61.89 $70.25 | ▲ +13.50% | ▲ +15.45% | $67.38 (+8.87%) |
May 15, 2026 20w ago | Press Release | $66.93 $59.56 | ▼ −11.01% | ▼ −13.13% | $67.38 (+0.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access